Genmab | GEN - Des Atouts

Prix De L'Action
1,790.00
Variation Quotidienne
-12.50 -0.69%
Mensuellement
1.91%
Annuel
46.12%
Q2 Prévisions
1,699.78




Des Atouts Changement Date
Agios Pharmaceuticals USD 1.3B 88.48M 2025-12
Almirall EUR 2.34B 29.21M 2025-12
Amarin USD 670.78M 10.96M 2025-12
Amgen USD 90.59B 445M 2025-12
argenx SE USD 7.18B 973.07M 2025-06
AstraZeneca USD 114.07B 382M 2025-12
Bayer EUR 104.54B 331M 2025-12
BioMarin Pharmaceutical USD 7.59B 20.85M 2025-12
Demant DKK 39.07B 6.43B 2025-12
Exelixis USD 2.84B 20.87M 2025-12
Fresenius Medical Care EUR 31B 115.33M 2025-12
Galapagos EUR 3.41B 105.39M 2025-12
Genmab DKK 12.87B 5.85B 2025-12
GlaxoSmithKline GBP 61.12B 221M 2025-12
GN Store Nord DKK 29.23B 170M 2025-12
GRIFOLS EUR 19.71B 141.77M 2025-12
Hikma Pharmaceutical USD 5.67B 117M 2025-12
Insmed USD 2.26B 96.18M 2025-12
Lonza CHF 18.97B 164M 2025-12
Merck EUR 51.53B 600M 2025-12
Novartis USD 110.95B 3.66B 2025-12
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Roche Holding CHF 100.7B 5.94B 2025-12
Sanofi EUR 126.81B 2.99B 2025-12
UCB EUR 18.16B 971M 2025-12